OTC: BCAB · Life Sciences · 3 alerts · CIK 1826892
Share price
$1.99Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioAtla, Inc. filings on SEC EDGAR ↗
BioAtla, Inc. reported a significant reduction in net loss to $13.8 million for the first nine months of 2026, compared to $49.8 million in the prior year, primarily driven by $6.8 million in collaboration revenue and a sharp decrease in R&D spending. However, the company's liquidity position is critical, with cash and cash equivalents dropping to $0.6 million as of September 30, 2026, and a total stockholders' deficit of $43.6 million.
BioAtla, Inc. entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, establishing a facility to sell up to $40.0 million of common stock at the company's option. Shares will be sold at 97% of the lowest daily VWAP over a three-day pricing period following an advance notice. As consideration, the company agreed to pay a $500,000 commitment fee, partially settled through the issuance of warrants for 182,110 shares.